Jazz Pharmaceuticals plc
Zepzelca
ES-SCLC
Resolved
188days ago
Phase 3 readout · ~ Dec 31, 2025 estimated
What's at stake
Phase 3 trial results for Zepzelca in ES-SCLC are due ~ Dec 31, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Received accelerated approval by FDA on August 6, 2025; 2FDA approval of Zepzelca in combination with Tecentriq (atezolizumab) as first-line maintenance therapy for ES-SCLC; 3Jazz Pharmaceuticals plc has not finalized its financial results ”